Literature DB >> 22136288

Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma.

Jeong Won Jang1, Ji-Yong Chun, Young Min Park, Soo-Kyung Shin, Wangdon Yoo, Soo-Ok Kim, Sun Pyo Hong.   

Abstract

This study explored the combined effect of number and pattern of mutations in the X/precore regions of the hepatitis B virus (HBV) genome, mutational complex genotype (MCG), on hepatocellular carcinoma (HCC) development. Sequence variations were determined by direct sequencing and multiplex restriction fragment mass polymorphism analysis in 150 age-, sex- and hepatitis B e antigen (HBeAg) status-matched patients with and without HCC. In addition, a longitudinal study and an external validation of MCG were conducted. All were HBV subgenotype C2. Eight high-frequency mutations (G1613A, C1653T, T1753V, A1762T, G1764A, A1846T, G1896A and G1899A) were significantly associated with HCC. Whereas C1653T, T1753V, G1764A and A1846T were independent mutational factors for HCC, the significance of these individual mutations was negligible when analyzed with all clinico-virological variables. The total number of mutations was the only independent viral factor for HCC, irrespective of HBeAg status. There was a significant dose-risk relationship between the number of mutations and HCC, in which high risks for HCC were associated with mutation numbers ≥ 6. Pattern analysis of the mutations revealed disparity in distribution among the top seven high-risk mutation combination patterns, which accounted for 40 and 2.7% of HCC and non-HCC cases, respectively. The predictive accuracy of the high-risk mutations for HCC was similar to that of α-fetoprotein. Longitudinal and external validation studies also supported the association of mutation number with HCC development. MCG in the HBV X/precore regions is a risk indicator for HCC, and might serve as a new guide to the HCC screening scheme for chronic HBV carriers.
© 2011 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22136288     DOI: 10.1111/j.1349-7006.2011.02170.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  20 in total

Review 1.  X region mutations of hepatitis B virus related to clinical severity.

Authors:  Hong Kim; Seoung-Ae Lee; Bum-Joon Kim
Journal:  World J Gastroenterol       Date:  2016-06-28       Impact factor: 5.742

Review 2.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 3.  Genetic variation of hepatitis B virus and its significance for pathogenesis.

Authors:  Zhen-Hua Zhang; Chun-Chen Wu; Xin-Wen Chen; Xu Li; Jun Li; Meng-Ji Lu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 4.  Clinical utility of complex mutations in the core promoter and proximal precore regions of the hepatitis B virus genome.

Authors:  Young Min Park
Journal:  World J Hepatol       Date:  2015-01-27

5.  First hepatitis B virus full-length genomic study among blood donors from Argentina: unexpected mutations in the circulating subgenotypes' proteins.

Authors:  C M Delfino; C Berini; W Pedrozo; R Malan; J Blejer; J R Oubiña; M M Biglione; V L Mathet
Journal:  Virus Genes       Date:  2014-12-24       Impact factor: 2.332

Review 6.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

7.  X protein mutations in hepatitis B virus DNA predict postoperative survival in hepatocellular carcinoma.

Authors:  Ying Xie; Shufeng Liu; Yue Zhao; Zhanjun Guo; Jinsheng Xu
Journal:  Tumour Biol       Date:  2014-07-19

8.  A novel mutant 10Ala/Arg together with mutant 144Ser/Arg of hepatitis B virus X protein involved in hepatitis B virus-related hepatocarcinogenesis in HepG2 cell lines.

Authors:  Ying Shi; Junwei Wang; Yuhe Wang; Anna Wang; Hongliang Guo; Feili Wei; Sanjay R Mehta; Stephen Espitia; Davey M Smith; Longgen Liu; Yulin Zhang; Dexi Chen
Journal:  Cancer Lett       Date:  2015-12-17       Impact factor: 8.679

9.  Quantitative evaluation of hepatitis B virus mutations and hepatocellular carcinoma risk: a meta-analysis of prospective studies.

Authors:  Yang Yang; Jiang-Wei Sun; Long-Gang Zhao; Freddie Bray; Yong-Bing Xiang
Journal:  Chin J Cancer Res       Date:  2015-10       Impact factor: 5.087

10.  Novel approach to identifying the hepatitis B virus pre-S deletions associated with hepatocellular carcinoma.

Authors:  Zhi-Mei Zhao; Yan Jin; Yu Gan; Yu Zhu; Tao-Yang Chen; Jin-Bing Wang; Yan Sun; Zhi-Gang Cao; Geng-Sun Qian; Hong Tu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.